# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The company announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RN...
HC Wainwright & Co. analyst Andrew Fein reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $5 price ta...
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and raises the price target from $2...
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.38) per share. This is a 61.09 percent increase over losses o...
Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human prima...